{"entity":{"id":"vincristine","kind":"drug","name":"Vincristine","aka":[],"tldr":"A plant-derived chemotherapy from the Madagascar periwinkle that has been in almost every childhood leukaemia and lymphoma regimen since the 1960s.","summary":"Approved 1963. Component of CHOP, ABVD-era regimens, ALL induction/maintenance, VAC/VDC (rhabdomyosarcoma, Ewing), Wilms tumour (VA/DD-4A), neuroblastoma and medulloblastoma regimens, EMA-CO. Fatal if given intrathecally; vincristine shortages (2019) disrupted paediatric care. Liposomal vincristine (Marqibo, 2012) for Ph-negative ALL was discontinued 2022.","status":"approved","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Vincristine","links":[{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=vincristine"}],"tags":["gap-fill","generic","who-essential"],"related":[],"cancers":["all-leukemia","dlbcl","hodgkin-lymphoma","rhabdomyosarcoma","ewing-sarcoma","wilms-tumor","neuroblastoma","medulloblastoma","retinoblastoma","oligodendroglioma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":["rtog-9402","eortc-26951","nct06097364","nct04529772","nct06717347","nct06191744","nct06911502","nct06091865","nct06091254","nct05888493","nct03407144","nct04663347","nct04542824","nct05201248","nct07730515","nct06564038","nct04623541","nct04980222","nct07387926","nct06947967","nct06425302"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Oncovin / Marqibo","modality":"Vinca alkaloid (microtubule inhibitor)","mechanism":"Binds β-tubulin and prevents microtubule polymerisation, arresting mitosis; dose-limited by peripheral neuropathy.","approvals":[{"region":"US","year":1963,"indication":"Acute leukaemia; Hodgkin and non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, Wilms tumour"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[{"date":"2012-08-09","type":"accelerated-approval","region":"US","note":"Accelerated approval on a surrogate endpoint, with a confirmatory trial required.","indication":"Adults with Philadelphia (PH) chromosome negative (-) ALL in second relapse or greater relapsed or whose disease has progressed following 2 or greater treatment lines of anti-leukemia therapies"},{"date":"2022-05-02","type":"withdrawal","region":"US","note":"Withdrawn: the indication came off the label 9.7 years after its accelerated approval.","indication":"Adults with Philadelphia (PH) chromosome negative (-) ALL in second relapse or greater relapsed or whose disease has progressed following 2 or greater treatment lines of anti-leukemia therapies"}]},"route":"/drugs/vincristine/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/"},{"id":"adult-t-cell-leukaemia-lymphoma","kind":"cancer","name":"Adult T-cell leukaemia/lymphoma","route":"/cancers/adult-t-cell-leukaemia-lymphoma/"},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/"},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/"},{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/"},{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"},{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/"},{"id":"desmoplastic-small-round-cell-tumour","kind":"cancer","name":"Desmoplastic small round cell tumour","route":"/cancers/desmoplastic-small-round-cell-tumour/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/"},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"gestational-trophoblastic","kind":"cancer","name":"Gestational trophoblastic neoplasia","route":"/cancers/gestational-trophoblastic/"},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/"},{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/"},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/"},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/"},{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/"},{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/"},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/"},{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/"},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/"},{"id":"monomorphic-epitheliotropic-intestinal-t-cell-lymphoma","kind":"cancer","name":"Monomorphic epitheliotropic intestinal T-cell lymphoma","route":"/cancers/monomorphic-epitheliotropic-intestinal-t-cell-lymphoma/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"},{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/"},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/"},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/"},{"id":"optic-pathway-glioma","kind":"cancer","name":"Optic pathway glioma","route":"/cancers/optic-pathway-glioma/"},{"id":"paediatric-low-grade-glioma","kind":"cancer","name":"Paediatric low-grade glioma","route":"/cancers/paediatric-low-grade-glioma/"},{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"},{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/"},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/"},{"id":"pineoblastoma","kind":"cancer","name":"Pineoblastoma","route":"/cancers/pineoblastoma/"},{"id":"pleuropulmonary-blastoma-dicer1","kind":"cancer","name":"Pleuropulmonary blastoma (types I, Ir, II and III)","route":"/cancers/pleuropulmonary-blastoma-dicer1/"},{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/"},{"id":"primary-testicular-lymphoma","kind":"cancer","name":"Primary large B-cell lymphoma of the testis","route":"/cancers/primary-testicular-lymphoma/"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/"},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/"},{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/"},{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/"},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/"},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/"},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/"},{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/"},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/"},{"id":"cipn-recovery-and-treatment","kind":"technology","name":"Nerve damage from chemotherapy: what recovers, and what helps","route":"/technologies/cipn-recovery-and-treatment/"},{"id":"small-molecule-api-synthesis","kind":"technology","name":"Small-molecule API synthesis","route":"/technologies/small-molecule-api-synthesis/"}],"company":[{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/"},{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}],"trial":[{"id":"nct04529772","kind":"trial","name":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","route":"/trials/nct04529772/"},{"id":"nct05888493","kind":"trial","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","route":"/trials/nct05888493/"},{"id":"nct06564038","kind":"trial","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","route":"/trials/nct06564038/"},{"id":"nct05382338","kind":"trial","name":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","route":"/trials/nct05382338/"},{"id":"nct06091865","kind":"trial","name":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa","route":"/trials/nct06091865/"},{"id":"nct06911502","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela","route":"/trials/nct06911502/"},{"id":"nct05201248","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th","route":"/trials/nct05201248/"},{"id":"nct06425302","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","route":"/trials/nct06425302/"},{"id":"nct04980222","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","route":"/trials/nct04980222/"},{"id":"nct06717347","kind":"trial","name":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi","route":"/trials/nct06717347/"},{"id":"nct06097364","kind":"trial","name":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo","route":"/trials/nct06097364/"},{"id":"nct06091254","kind":"trial","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","route":"/trials/nct06091254/"},{"id":"acns0121","kind":"trial","name":"ACNS0121","route":"/trials/acns0121/"},{"id":"acns0333","kind":"trial","name":"ACNS0333","route":"/trials/acns0333/"},{"id":"acns1422","kind":"trial","name":"ACNS1422","route":"/trials/acns1422/"},{"id":"actg-a5263","kind":"trial","name":"ACTG A5263/AMC 066","route":"/trials/actg-a5263/"},{"id":"aews0031","kind":"trial","name":"AEWS0031","route":"/trials/aews0031/"},{"id":"ahl2011","kind":"trial","name":"AHL2011","route":"/trials/ahl2011/"},{"id":"ahod1331","kind":"trial","name":"AHOD1331","route":"/trials/ahod1331/"},{"id":"calgb-50303","kind":"trial","name":"Alliance/CALGB 50303","route":"/trials/calgb-50303/"},{"id":"anbl17p1","kind":"trial","name":"ANBL17P1","route":"/trials/anbl17p1/"},{"id":"arched","kind":"trial","name":"ARCHED","route":"/trials/arched/"},{"id":"nct07730515","kind":"trial","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","route":"/trials/nct07730515/"},{"id":"codel","kind":"trial","name":"CODEL","route":"/trials/codel/"},{"id":"acns0331","kind":"trial","name":"COG ACNS0331","route":"/trials/acns0331/"},{"id":"acns0332","kind":"trial","name":"COG ACNS0332","route":"/trials/acns0332/"},{"id":"aren0532","kind":"trial","name":"COG AREN0532","route":"/trials/aren0532/"},{"id":"aren0533","kind":"trial","name":"COG AREN0533","route":"/trials/aren0533/"},{"id":"nct02883049","kind":"trial","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","route":"/trials/nct02883049/"},{"id":"nct00557193","kind":"trial","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","route":"/trials/nct00557193/"},{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/"},{"id":"enrich","kind":"trial","name":"ENRICH","route":"/trials/enrich/"},{"id":"eortc-26951","kind":"trial","name":"EORTC 26951","route":"/trials/eortc-26951/"},{"id":"eortc-h10","kind":"trial","name":"EORTC/LYSA/FIL H10","route":"/trials/eortc-h10/"},{"id":"nct02890602","kind":"trial","name":"Erythropoietin for Management of Anemia Caused by Chemotherapy","route":"/trials/nct02890602/"},{"id":"euronet-phl-c2","kind":"trial","name":"EuroNet-PHL-C2","route":"/trials/euronet-phl-c2/"},{"id":"flyer","kind":"trial","name":"FLYER","route":"/trials/flyer/"},{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/"},{"id":"hd18","kind":"trial","name":"GHSG HD18","route":"/trials/hd18/"},{"id":"goya","kind":"trial","name":"GOYA","route":"/trials/goya/"},{"id":"nct04221035","kind":"trial","name":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","route":"/trials/nct04221035/"},{"id":"nct03150693","kind":"trial","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","route":"/trials/nct03150693/"},{"id":"inter-b-nhl-ritux-2010","kind":"trial","name":"Inter-B-NHL Ritux 2010","route":"/trials/inter-b-nhl-ritux-2010/"},{"id":"nct01117441","kind":"trial","name":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","route":"/trials/nct01117441/"},{"id":"jcog9801","kind":"trial","name":"JCOG9801","route":"/trials/jcog9801/"},{"id":"mosun-len-mzl","kind":"trial","name":"Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma","route":"/trials/mosun-len-mzl/"},{"id":"polar-bear","kind":"trial","name":"POLAR BEAR","route":"/trials/polar-bear/"},{"id":"nct06220032","kind":"trial","name":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","route":"/trials/nct06220032/"},{"id":"prima-follicular","kind":"trial","name":"PRIMA","route":"/trials/prima-follicular/"},{"id":"ptld-1","kind":"trial","name":"PTLD-1","route":"/trials/ptld-1/"},{"id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/"},{"id":"nct00057811","kind":"trial","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","route":"/trials/nct00057811/"},{"id":"rtog-9402","kind":"trial","name":"RTOG 9402","route":"/trials/rtog-9402/"},{"id":"nct07387926","kind":"trial","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","route":"/trials/nct07387926/"},{"id":"nct03407144","kind":"trial","name":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","route":"/trials/nct03407144/"},{"id":"nct04623541","kind":"trial","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","route":"/trials/nct04623541/"},{"id":"nct04663347","kind":"trial","name":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","route":"/trials/nct04663347/"},{"id":"sjmb12","kind":"trial","name":"SJMB12","route":"/trials/sjmb12/"},{"id":"nct06191744","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct06191744/"},{"id":"tadpole","kind":"trial","name":"TADPOLE (CDRB436G2201)","route":"/trials/tadpole/"},{"id":"nct01700946","kind":"trial","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","route":"/trials/nct01700946/"},{"id":"nct00136084","kind":"trial","name":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","route":"/trials/nct00136084/"},{"id":"nct03206671","kind":"trial","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","route":"/trials/nct03206671/"},{"id":"nct04542824","kind":"trial","name":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","route":"/trials/nct04542824/"},{"id":"triangle","kind":"trial","name":"TRIANGLE","route":"/trials/triangle/"},{"id":"trog-99-03","kind":"trial","name":"TROG 99.03","route":"/trials/trog-99-03/"},{"id":"nct06947967","kind":"trial","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","route":"/trials/nct06947967/"}],"term":[{"id":"foxo1-fusion-status","kind":"term","name":"FOXO1 fusion status and IRS group (rhabdomyosarcoma)","route":"/terms/foxo1-fusion-status/"},{"id":"histological-response-induction","kind":"term","name":"Histological response to induction chemotherapy (osteosarcoma and Ewing sarcoma)","route":"/terms/histological-response-induction/"},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/"},{"id":"r-chop","kind":"term","name":"R-CHOP (lymphoma chemoimmunotherapy)","route":"/terms/r-chop/"},{"id":"lymphoma-tx-regimen-alphabet","kind":"term","name":"The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest","route":"/terms/lymphoma-tx-regimen-alphabet/"},{"id":"wilms-risk-markers","kind":"term","name":"Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups)","route":"/terms/wilms-risk-markers/"}],"paper":[{"id":"paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020","kind":"paper","name":"ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings","route":"/key-papers/paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020/"},{"id":"paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019","kind":"paper","name":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303","route":"/key-papers/paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019/"},{"id":"paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017","kind":"paper","name":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial","route":"/key-papers/paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017/"},{"id":"paper-casulo-pod24-follicular-lymphoma-jco-2015","kind":"paper","name":"Early relapse of follicular lymphoma after R-CHOP defines patients at high risk for death: an analysis from the National LymphoCare Study","route":"/key-papers/paper-casulo-pod24-follicular-lymphoma-jco-2015/"},{"id":"paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997","kind":"paper","name":"EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients","route":"/key-papers/paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997/"},{"id":"paper-eortc-26951-van-den-bent-jco-2013","kind":"paper","name":"EORTC 26951: adjuvant PCV after radiotherapy for anaplastic oligodendroglial tumours, long-term follow-up","route":"/key-papers/paper-eortc-26951-van-den-bent-jco-2013/"},{"id":"paper-flyer-four-vs-six-cycles-r-chop-lancet-2019","kind":"paper","name":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER)","route":"/key-papers/paper-flyer-four-vs-six-cycles-r-chop-lancet-2019/"},{"id":"paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025","kind":"paper","name":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial","route":"/key-papers/paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025/"},{"id":"paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017","kind":"paper","name":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","route":"/key-papers/paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017/"},{"id":"paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019","kind":"paper","name":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","route":"/key-papers/paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019/"},{"id":"paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017","kind":"paper","name":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/"},{"id":"paper-polarix-polatuzumab-rchp-nejm-2022","kind":"paper","name":"POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma","route":"/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/"},{"id":"paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019","kind":"paper","name":"Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)","route":"/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/"},{"id":"paper-trog-99-03-radiotherapy-systemic-therapy-early-follicular-jco-2018","kind":"paper","name":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","route":"/key-papers/paper-trog-99-03-radiotherapy-systemic-therapy-early-follicular-jco-2018/"},{"id":"paper-rtog-9802-buckner-nejm-2016","kind":"paper","name":"RTOG 9802: radiation plus procarbazine, lomustine and vincristine in high-risk low-grade glioma","route":"/key-papers/paper-rtog-9802-buckner-nejm-2016/"},{"id":"paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007","kind":"paper","name":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","route":"/key-papers/paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007/"}],"idea":[{"id":"lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas","kind":"idea","name":"Randomised evidence for the T-cell lymphomas, including the ones that are not in Europe or North America","route":"/ideas/lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas/"},{"id":"lymphoma-ev-the-drugs-that-cure-and-the-places-without-them","kind":"idea","name":"The drugs that cure lymphoma, and the places that do not have them","route":"/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/"}],"target":[{"id":"tubulin","kind":"target","name":"Tubulin (microtubules)","route":"/targets/tubulin/"}],"person":[{"id":"donald-pinkel","kind":"person","name":"Donald Pinkel","route":"/people/donald-pinkel/"},{"id":"emil-freireich","kind":"person","name":"Emil J Freireich","route":"/people/emil-freireich/"}],"drug":[{"id":"tk216","kind":"drug","name":"TK216","route":"/drugs/tk216/"},{"id":"vindesine","kind":"drug","name":"Vindesine","route":"/drugs/vindesine/"}],"pathway":[{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/"}],"roadmap":[{"id":"chemotherapy-roadmap","kind":"roadmap","name":"Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs","route":"/roadmaps/chemotherapy-roadmap/"},{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"},{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/"}]}}